Cardiometabolic risk factors efficacy of semaglutide in the STEP program

Jan 24, 2023Postgraduate medicine

Semaglutide’s effects on heart and metabolism risk factors in the STEP program

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗OA ↗

Abstract

Once-weekly subcutaneous semaglutide 2.4 mg is associated with significant weight loss and improvements in cardiometabolic parameters compared to placebo.

Semaglutide treatment resulted in greater reductions in body weight, waist circumference, and body mass index than placebo.
Improvements in systolic and diastolic blood pressure were observed with semaglutide compared to placebo.
Positive changes in glycated hemoglobin, C-reactive protein, and lipid levels were noted with semaglutide treatment.
In a follow-up period, continued semaglutide use showed further reductions in glycated hemoglobin and improvements in lipid profiles.
The findings across the STEP trials suggest semaglutide 2.4 mg may effectively improve cardiometabolic risk factors associated with obesity.

AI simplified

People with overweight or obesity often suffer from associated cardiometabolic diseases and comorbidities. Current therapies for obesity include lifestyle intervention, bariatric surgery, and pharmacotherapy. The magnitude of weight loss achieved with these therapies can determine the level of improvement in various comorbidities. Once-weekly subcutaneous semaglutide 2.4 mg is a glucagon-like peptide-1 receptor agonist recently approved by the US Food and Drug Administration for the treatment of obesity. This article reviews data from the global phase 3 Semaglutide Treatment Effect in People with obesity (STEP) program, comparing the efficacy of once-weekly subcutaneous semaglutide 2.4 mg versus placebo for weight loss and improvements in cardiometabolic parameters across the STEP 1 to 5 trials. In STEP 1 to 3 and STEP 5, semaglutide led to greater reductions from baseline versus placebo in body weight, waist circumference, body mass index, systolic blood pressure (SBP), and diastolic blood pressure, as well as positive changes in glycated hemoglobin (HbA), C-reactive protein, and lipid levels. In STEP 4, all participants had a 20-week run-in period on semaglutide before either continuing on semaglutide or switching to placebo at week 20 in a 2:1 ratio for 48 weeks. At week 68, continued semaglutide led to further reductions from week 20 in HbA, improvements in lipid profile, and stabilization of SBP. Overall, across the STEP trials, treatment with semaglutide 2.4 mg versus placebo improved cardiometabolic risk factors associated with obesity, illustrating an effective treatment option for people with overweight (and associated comorbidities) or obesity. 1c1c

Full Text

Full text is available at the source.

View full text ↗

Cardiometabolic risk factors efficacy of semaglutide in the STEP program

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief